Liraglutide Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Victoza is expected to register the highest growth rate over the forecast period.

Victoza is used with a diet and exercise program to control blood sugar levels in adults and children 10 years of age and older with type-2 diabetes when other medications did not control levels well. Victoza is also used to reduce the risk of a heart attack, stroke, or mortality in adults with type-2 diabetes mellitus and heart and blood vessel disease. Victoza is not used to treat type 1 diabetes or diabetic ketoacidosis in adults.

Teva Pharmaceuticals agreed to a patent litigation settlement with Novo Nordisk that would see the generic drugmaker wait until December 2023 to begin marketing its generic version of the type-2 diabetes drug Victoza. Novo Nordisk filed a lawsuit in March 2017 after Teva submitted an ANDA application to the FDA seeking approval for a generic version of the drug. Novo Nordisk alleged that Teva was engaging in patent infringement. The Federal Trade Commission and the Department of Justice awarded Teva a license to launch a generic version of Victoza starting December 22, 2023.

The growth of the studied market is being supported by the increasing prevalence of obesity, type 2 diabetes, and cardiovascular disorders worldwide. Rising consumption of calorie-dense foods, declining physical activity levels, and other lifestyle-related risk factors have contributed to a growing population requiring long-term metabolic disease management. For instance, according to the World Obesity Atlas 2024, the global number of individuals living with overweight and obesity is projected to continue increasing over the coming years, highlighting the expanding burden of weight-related health conditions. As obesity is a major risk factor for type 2 diabetes and cardiovascular diseases, the rising patient population is expected to drive demand for GLP-1 agonists during the forecast period. The World Health Organization predicted that by 2025, roughly 167 million people are likely to become overweight or obese. Furthermore, as per World Obesity Atlas 2023, the estimates for global levels of overweight and obesity (BMI ≥25kg/m²) suggest that over 4 billion people may be affected by 2035. The prevalence of obesity (BMI ≥30kg/m²) alone is anticipated to rise to 24% of the population over the same period, affecting nearly 2 billion adults, children, and adolescents by 2035.

Hence, owing to the high burden of obesity, the increasing prevalence of diabetes and expected new product launches are expected to fuel market growth over the forecast period.

North America held the highest market share in the current year

The North American region held the highest market share in the current year.

In the North American region, the prevalence of diabetes has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes owing to less physical activity, unhealthy food habits, and other lifestyle factors. According to the Centers for Disease Control and Prevention (CDC) press release in November 2023, more than one in three Americans are at increased risk for type 2 diabetes. Furthermore, more than 1 in 3 adults, i.e., about 98 million Americans, have prediabetes, and 81% of them are unaware of the condition. Similarly, the Government of Canada in October 2022 estimated that over 3 million Canadians, or 8.9% of the population, have been diagnosed with diabetes. After adjusting for the aging population over time, the prevalence has been increasing at an average rate of 3.3% per year. In addition, 6.1% of Canadian adults have prediabetes, putting them at high risk of developing type-2 diabetes.

Leading diabetes and endocrinology organizations, including the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and other clinical bodies, have increasingly emphasized the use of GLP-1 receptor agonists for improving glycemic control and reducing cardiometabolic risk in appropriate patient populations. Updated treatment guidelines have expanded the role of liraglutide as an effective option for patients requiring better blood glucose management, weight reduction, and cardiovascular risk mitigation.

The Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report 2022 estimated that more than 130 million adults are living with diabetes or prediabetes in the United States. Type-2 diabetes is more common, and diabetes is more consequential among communities of color, those who live in rural areas, and those with less education, lower incomes, and lower health literacy.

Therefore, the studied market is anticipated to grow over the analysis period due to rising prevalence and the factors above.